ÖYÖzgür Mehmet Yis

Özgür Mehmet Yis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Özgür Mehmet Yis has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gingival Crevicular Fluid Levels of Parathyroid Hormone-Related Protein, RANK Ligand, and Osteoprotegerin in Periodontal Health, Gingivitis, and Periodontitis: A Cross-Sectional Study

    by Bilge Meracı Yıldıran, Nuray Ercan, Esra Ateş Yıldırım, Zeynep Akgül, Özgür Mehmet Yis

    Background/Objectives: Parathyroid hormone-related protein (PTHrP) modulates the receptor activator of nuclear factor kappa B ligand (RANKL)/osteoprotegerin (OPG) system in periodontal cells in vitro but has not been measured in gingival crevicular fluid (GCF). This study compared GCF PTHrP, RANKL, and OPG across periodontal health, gingivitis, and periodontitis. Methods: This cross-sectional study included 81 participants with periodontal health, gingivitis, or stage III grade B periodontitis (n = 27 each). GCF was collected from two interproximal sites per participant. PTHrP, RANKL, and OPG were quantified by ELISA and expressed as total amount per site and concentration. Group comparisons were repeated with adjustment for age and sex. Results: PTHrP total amount differed between all three groups, with values of 4.26 ± 2.96, 12.45 ± 5.77, and 19.67 ± 4.59 pg/site in periodontal health, gingivitis, and periodontitis, respectively (p < 0.001). RANKL total amount did not differ among groups (median: 51.40, 51.40, and 51.78 pg/site; p = 0.977). OPG total amount was lower (median: 53.36, 46.70, and 46.70 pg/site; p < 0.001) and the RANKL/OPG ratio higher (median: 0.98, 1.10, and 1.14; p < 0.001) in both disease groups than in periodontal health. After adjustment, PTHrP and OPG differences persisted, whereas no pairwise difference in the RANKL/OPG ratio remained significant. PTHrP correlated negatively with OPG (r = −0.530) and positively with the RANKL/OPG ratio (r = 0.481; both adjusted p < 0.001). Conclusions: GCF PTHrP total amount differed between periodontal health, gingivitis, and periodontitis, with the highest values in periodontitis. These cross-sectional findings identify an association between GCF PTHrP and periodontal status but do not establish a causal role for PTHrP in periodontal tissue breakdown.

  • Open Access

    Altered Gas6/sMerTK Balance in Gingival Crevicular Fluid Across Periodontal Health, Gingivitis, and Periodontitis: A Cross-Sectional Study

    by Nuray Ercan, Bilge Meracı Yıldıran, Zeynep Akgül, Esra Ateş Yıldırım, Özgür Mehmet Yis

    Background/Objectives: Periodontitis reflects a dysregulated inflammatory response in which impaired resolution and efferocytosis may play a central role. The TAM receptor MerTK and its ligand growth arrest-specific-6 (Gas6) are key regulators of these processes; however, their profile in gingival crevicular fluid (GCF) across the periodontal disease spectrum remains unclear. This cross-sectional study aimed to evaluate GCF levels of Gas6 and soluble MerTK (sMerTK) in individuals with periodontal health, gingivitis, and periodontitis, and to examine their associations with clinical periodontal parameters. Methods: Eighty-one systemically healthy adults were enrolled into three groups: periodontal health, gingivitis, and periodontitis. Full-mouth clinical periodontal measurements were recorded. Gas6 and sMerTK levels were quantified by enzyme-linked immunosorbent assay. Results: sMerTK progressively decreased from periodontal health to gingivitis and periodontitis, with significant differences among all groups (p < 0.001). Gas6 total amount was higher in the diseased groups, whereas its concentration decreased. The Gas6/sMerTK ratio increased stepwise with disease severity (p < 0.001), showing positive correlations with clinical attachment loss and other clinical periodontal parameters, while sMerTK showed inverse correlations. Conclusions: These findings suggest that the local GCF Gas6/sMerTK balance is altered across periodontal states, primarily due to a marked reduction in sMerTK. The Gas6/sMerTK ratio may represent a potential exploratory indicator of periodontal inflammatory status, although longitudinal validation is required.

  • Open Access

    Protective Effects of Gallic Acid on Oxidative and Inflammatory Markers in the Hippocampus and Prefrontal Cortex of a Ketamine-Induced Schizophrenia-like Model

    by Ali Osman Arslan, Ihsan Cetin, Ozgur Mehmet Yis, Sevdenur Akcay, Guven Akcay

    Background: Schizophrenia is a chronic neuropsychiatric disorder characterized by cognitive impairment, behavioral abnormalities, neuroinflammation, and oxidative stress. Increasing evidence suggests that dysregulated inflammatory cytokines and impaired antioxidant defenses contribute to schizophrenia pathophysiology. This study investigated the neuroprotective and anti-inflammatory effects of Gallic Acid (GA) in a ketamine-induced experimental schizophrenia model. Methods: Thirty male Balb/C mice were randomly divided into control, ketamine, and ketamine + GA groups. Schizophrenia was induced with ketamine (25 mg/kg/day) for 7 days, while the treatment group additionally received GA (60 mg/kg/day) for another 7 days. Behavioral tests, including open field, novel object recognition, and tail suspension tests, were performed to evaluate locomotor activity, cognition, and depressive-like behavior. Tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-18 (IL-18), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), total antioxidant status (TAS), and total oxidant status (TOS) levels were analyzed in hippocampal and prefrontal cortex tissues to assess inflammatory and oxidative stress-related alterations. Results: Ketamine induced schizophrenia-like behaviors, including hyperlocomotion, memory impairment, and increased immobility. These behavioral alterations were accompanied by significantly elevated TNF-α, IL-1β, IL-18, and TOS levels, alongside reduced SOD, CAT, GSH-Px, and TAS levels in the hippocampus and prefrontal cortex. GA treatment ameliorated behavioral impairments, restored antioxidant enzymes, increased TAS levels, and reduced pro-inflammatory cytokines and TOS in these brain regions. Conclusions: GA exerted neuroprotective effects in the ketamine-induced schizophrenia model by reducing oxidative stress, neuroinflammation, and behavioral deficits. These findings suggest that Gallic Acid may serve as a promising therapeutic candidate for schizophrenia through modulation of inflammatory and oxidative stress pathways.